SNDX

insider transactions

Syndax Pharmaceuticals Inc — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-327.3K

0 buy · 327.3K sell

Net value · 365d

-$5.5M

$0 in · $5.5M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 327.3K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 365d

Open-market Buys Sells All types

Sell·S
Jun 12, 26

Botwood Nicholas A.J.

Head of R&D, CMO · 10b5-1

$1.2M

65.5K sh · $18.07 avg · 2 lots

Own -52%
Sell·S
Jun 1, 26

Metzger Michael A KEY

Chief Executive Officer

$130.0K

6.8K sh · $18.99

Own -1%
Sell·S
Jun 1, 26

Goldan Keith A. KEY

Chief Financial Officer

$22.4K

1.2K sh · $18.99

Own -1%
Sell·S
Feb 9, 26

Metzger Michael A KEY

Chief Executive Officer

$360.9K

17.2K sh · $21.03

Own -3%
Sell·S
Feb 9, 26

Goldan Keith A. KEY

Chief Financial Officer

$71.7K

3.4K sh · $21.03

Own -2%
Sell·S
Feb 6, 26

Metzger Michael A KEY

Chief Executive Officer

$152.8K

7.4K sh · $20.62

Own -1%
Sell·S
Feb 6, 26

Goldan Keith A. KEY

Chief Financial Officer

$42.9K

2.1K sh · $20.62

Own -1%
Sell·S
Sep 8, 25

Metzger Michael A KEY

Chief Executive Officer · 10b5-1

$2.6M

157.3K sh · $16.41

Own -34%
Sell·S
Aug 18, 25

Podlesak Dennis

Director · 10b5-1

$874.9K

57.6K sh · $15.19 avg · 3 lots

Own -23%
Sell·S
Jul 16, 25

Goldan Keith A. KEY

Chief Financial Officer

$12.0K

1.3K sh · $9.29

Own -1%
Sell·S
Jul 16, 25

Metzger Michael A KEY

Chief Executive Officer

$70.0K

7.5K sh · $9.29

Own -2%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 12, 2026	Botwood Nicholas A.J. 10b5-1	Head of R&D, CMO	Sell S	65.5K2 lots	-52%	$18.07 avg	$1.2M
Jun 1, 2026	Metzger Michael A KEY	Chief Executive Officer	Sell S	6.8K	-1%	$18.99	$130.0K
Jun 1, 2026	Goldan Keith A. KEY	Chief Financial Officer	Sell S	1.2K	-1%	$18.99	$22.4K
Feb 9, 2026	Metzger Michael A KEY	Chief Executive Officer	Sell S	17.2K	-3%	$21.03	$360.9K
Feb 9, 2026	Goldan Keith A. KEY	Chief Financial Officer	Sell S	3.4K	-2%	$21.03	$71.7K
Feb 6, 2026	Metzger Michael A KEY	Chief Executive Officer	Sell S	7.4K	-1%	$20.62	$152.8K
Feb 6, 2026	Goldan Keith A. KEY	Chief Financial Officer	Sell S	2.1K	-1%	$20.62	$42.9K
Sep 8, 2025	Metzger Michael A KEY 10b5-1	Chief Executive Officer	Sell S	157.3K	-34%	$16.41	$2.6M
Aug 18, 2025	Podlesak Dennis 10b5-1	Director	Sell S	57.6K3 lots	-23%	$15.19 avg	$874.9K
Jul 16, 2025	Goldan Keith A. KEY	Chief Financial Officer	Sell S	1.3K	-1%	$9.29	$12.0K
Jul 16, 2025	Metzger Michael A KEY	Chief Executive Officer	Sell S	7.5K	-2%	$9.29	$70.0K

Buy Sell Non-market (grant · exercise · gift)

About SNDX insider trading

This page tracks insider transactions for Syndax Pharmaceuticals Inc (SNDX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.